Vertex Pharma drops as UnitedHealth offers Tier 3 coverage for new pain medicine
Vertex Pharma (VRTX) stock slips as UnitedHealth (UNH) offers its pain drug Journavx Tier 3 coverage, setting a rivalry with ...
Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
BioPharma Dive5h
Tris to ask for approval of dual-acting pain drug
Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...
Investing.com India2h
UnitedHealth includes Vertex’s non-opioid painkiller in coverage, but at a higher cost - Bloomberg
Investing.com -- Vertex Pharmaceuticals Inc (NASDAQ: VRTX ).’s newly approved non-opioid pain medication, Journavx, has been included in UnitedHealth Group Inc (NYSE: UNH ).’s coverage, according to ...
Fierce Biotech7h
Tris' next-gen pain drug completes trio of clinical wins, setting up push to FDA
Tris Pharma’s opioid alternative has scored a third win in a trio of clinical trials, providing the biotech with the data ...
Pharmabiz8h
Patients and experts urge Court to ensure access to cystic fibrosis in India
The patients of cystic fibrosis (CF), their families, and public health experts are pinning their hopes on the expected outcome from the Karnataka High Court regarding availability of affordable ...
Vertex non-opioid pain drug picked up by UnitedHealth
Vertex Pharmaceuticals’ (VRTX) non-opioid pain drug Journavx was picked up by UnitedHealth’s (UNH) Optum on “Tier 3.” The insurer said, ...
Global Biosensors Market to Show Positive Growth at a CAGR of ~8% by 2032 | DelveInsight
DelveInsight's Biosensors Market Insights report provides the current and forecast market analysis, individual leading biosensors ...